LONDON: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company specialising in iron deficiency, announces that Anders Lundstrom has been appointed as Chief Executive Officer (CEO) with effect from 01 February 2025. Anders joined the Board of Shield in May 2021 and was appointed as interim Chief Executive Officer on 24 July 2024. He…